Penumbra, Inc. (NYSE:PEN) reported third-quarter 2026 financial results on October 29, 2026, disclosing revenue of $410.1 million and noting it will not provide full-year guidance due to a pending acquisition by Boston Scientific Corporation.

Key Highlights

  • Total revenue of $410.1 million in Q3 2026, an increase of 15.6% compared to Q3 2025, according to the filing.
  • Global thrombectomy revenue of $279.2 million, up 18.1% year over year, with U.S. VTE revenue increasing 26.0% compared to the same period a year ago.
  • Gross profit margin of 68.3% in Q3 2026, an increase of 0.5% compared to Q3 2025.
  • Net income of $42.3 million in Q3 2026, compared to $45.9 million in Q3 2025, the company reported.
  • Total operating expenses included $7.1 million in acquisition-related expenses associated with the pending acquisition by Boston Scientific Corporation (NYSE:BSX).
  • No full-year 2026 financial guidance will be provided and no conference call will be hosted, the company disclosed, citing the pending Boston Scientific acquisition.

Penumbra Reports Q3 2026 Results Amid Pending Boston Scientific Acquisition

According to the filing, Penumbra reported total revenue of $410,145 thousand for the three months ended September 30, 2026, compared to $354,685 thousand in the same period of 2025, representing a 15.6% increase. U.S. revenue was $324,248 thousand, up 17.9%, while international revenue reached $85,897 thousand, up 7.8%. For the nine months ended September 30, 2026, total revenue was $1,174,949 thousand, a 15.4% increase from $1,018,280 thousand in the prior-year period.

By product category, the company disclosed that thrombectomy revenue for Q3 2026 was $279,157 thousand, an 18.1% increase, and embolization and access revenue was $130,988 thousand, up 10.8%. U.S. neuro revenue was reported at $77.9 million, an increase of 19.3% compared to Q3 2025. Gross profit for the quarter was $280,303 thousand, reflecting a gross margin of 68.3%. Income from operations was $50,739 thousand, and net income was $42,279 thousand, or $1.07 per diluted share, the filing stated.

Total operating expenses of $229,564 thousand included research and development costs of $25,361 thousand and selling, general and administrative expenses of $204,203 thousand. The SG&A figure, according to the filing, includes $7.1 million of acquisition-related expenses tied to the pending acquisition of Penumbra by Boston Scientific Corporation (NYSE:BSX). As of September 30, 2026, the company reported total assets of $2,025,103 thousand and total stockholders' equity of $1,583,509 thousand. The filing noted that, given the pending acquisition, the company will not provide full-year 2026 financial guidance or host a conference call to discuss Q3 results.

What Was Disclosed

Penumbra filed its Q3 2026 earnings press release disclosing revenue of $410.1 million, net income of $42.3 million, a gross margin of 68.3%, and $7.1 million in acquisition-related expenses, while declining to issue full-year guidance due to the pending Boston Scientific acquisition.